Differences in TRAIL-induced changes of Mcl-1 expression among distinct human colon epithelial cell lines

Experimental Cell Research

Volumn 315, Issue 19, 2009, Pages 3259-3266

  Vaculová, Alena ^a   Hofmanová, Jiřina ^a   Zatloukalová, Jiřina ^a   Kozubík, Alois ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

Author keywords

Apoptosis; Colon; ERK; Mcl 1; Survival; TRAIL

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MCL 1; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL STRAIN HCT116; CELL STRAIN HT29; CELL SURVIVAL; COLON ADENOCARCINOMA; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; DISEASE COURSE; DRUG DESIGN; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; FETUS; HUMAN; HUMAN CELL; INHIBITION KINETICS; LYMPH NODE METASTASIS; MITOCHONDRIAL MEMBRANE POTENTIAL; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 70350408333     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.09.019     Document Type: Article

References (43)

1. Kozopas K.M., Yang T., Buchan H.L., Zhou P., and Craig R.W. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 3516-3520
2. Rinkenberger J.L., Horning S., Klocke B., Roth K., and Korsmeyer S.J. Mcl-1 deficiency results in peri-implantation embryonic lethality. Genes Dev. 14 (2000) 23-27
3. Zhuang J., and Brady H.J. Emerging role of Mcl-1 in actively counteracting BH3-only proteins in apoptosis. Cell. Death Differ. 13 (2006) 1263-1267
4. Craig R.W. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 16 (2002) 444-454
5. Saxena A., Moshynska O.V., Moshynskyy I.D., Neuls E.D., Qureshi T., Bosch M., Voralia M., and Bonham K. Short nucleotide polymorphic insertions in the MCL-1 promoter affect gene expression. Cancer Lett. 251 (2007) 114-131
6. Bae J., Leo C.P., Hsu S.Y., and Hsueh A.J. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J. Biol. Chem. 275 (2000) 25255-25261
7. Weng C., Li Y., Xu D., Shi Y., and Tang H. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J. Biol. Chem. 280 (2005) 10491-10500
8. Han J., Goldstein L.A., Gastman B.R., and Rabinowich H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J. Biol. Chem. 281 (2006) 10153-10163
9. Han J., Goldstein L.A., Gastman B.R., Froelich C.J., Yin X.M., and Rabinowich H. Degradation of Mcl-1 by granzyme B: implications for Bim-mediated mitochondrial apoptotic events. J. Biol. Chem. 279 (2004) 22020-22029
10. Zhong Q., Gao W., Du F., and Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121 (2005) 1085-1095
11. Maurer U., Charvet C., Wagman A.S., Dejardin E., and Green D.R. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell. 21 (2006) 749-760
12. Domina A.M., Vrana J.A., Gregory M.A., Hann S.R., and Craig R.W. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 23 (2004) 5301-5315
13. Inoshita S., Takeda K., Hatai T., Terada Y., Sano M., Hata J., Umezawa A., and Ichijo H. Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J. Biol. Chem. 277 (2002) 43730-43734
14. Kobayashi S., Lee S.H., Meng X.W., Mott J.L., Bronk S.F., Werneburg N.W., Craig R.W., Kaufmann S.H., and Gores G.J. Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J. Biol. Chem. 282 (2007) 18407-18417
15. Song L., Coppola D., Livingston S., Cress D., and Haura E.B. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol. Ther. 4 (2005) 267-276
16. Sieghart W., Losert D., Strommer S., Cejka D., Schmid K., Rasoul-Rockenschaub S., Bodingbauer M., Crevenna R., Monia B.P., Peck-Radosavljevic M., and Wacheck V. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J. Hepatol. 44 (2006) 151-157
17. Okaro A.C., Deery A.R., Hutchins R.R., and Davidson B.R. The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. J. Clin. Pathol. 54 (2001) 927-932
18. Backus H.H., van Riel J.M., van Groeningen C.J., Vos W., Dukers D.F., Bloemena E., Wouters D., Pinedo H.M., and Peters G.J. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann. Oncol. 12 (2001) 779-785
19. Taniai M., Grambihler A., Higuchi H., Werneburg N., Bronk S.F., Farrugia D.J., Kaufmann S.H., and Gores G.J. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 64 (2004) 3517-3524
20. Meng X.W., Lee S.H., Dai H., Loegering D., Yu C., Flatten K., Schneider P., Dai N.T., Kumar S.K., Smith B.D., Karp J.E., Adjei A.A., and Kaufmann S.H. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J. Biol. Chem. 282 (2007) 29831-29846
21. Ricci M.S., Kim S.H., Ogi K., Plastaras J.P., Ling J., Wang W., Jin Z., Liu Y.Y., Dicker D.T., Chiao P.J., Flaherty K.T., Smith C.D., and El-Deiry W.S. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell. 12 (2007) 66-80
22. Schulze-Bergkamen H., Ehrenberg R., Hickmann L., Vick B., Urbanik T., Schimanski C.C., Berger M.R., Schad A., Weber A., Heeger S., Galle P.R., and Moehler M. Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. World J. Gastroenterol. 14 (2008) 3829-3840
23. Schulze-Bergkamen H., Fleischer B., Schuchmann M., Weber A., Weinmann A., Krammer P.H., and Galle P.R. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. BMC Cancer. 6 (2006) 232
24. Gomez-Benito M., Martinez-Lorenzo M.J., Anel A., Marzo I., and Naval J. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Exp. Cell. Res. 313 (2007) 2378-2388
25. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., and Goodwin R.G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
26. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C., and Lynch D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 (1999) 157-163
27. Falschlehner C., Emmerich C.H., Gerlach B., and Walczak H. TRAIL signalling: decisions between life and death. Int. J. Biochem. Cell. Biol. 39 (2007) 1462-1475
28. Vaculova A., Hofmanova J., Soucek K., Andera L., and Kozubik A. Ethanol acts as a potent agent sensitizing colon cancer cells to the TRAIL-induced apoptosis. FEBS Lett. 577 (2004) 309-313
29. Schulze-Bergkamen H., Brenner D., Krueger A., Suess D., Fas S.C., Frey C.R., Dax A., Zink D., Buchler P., Muller M., and Krammer P.H. Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt. Hepatology 39 (2004) 645-654
30. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 (2001) 402-408
31. Secchiero P., Gonelli A., Carnevale E., Milani D., Pandolfi A., Zella D., and Zauli G. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107 (2003) 2250-2256
32. Secchiero P., Zerbinati C., Rimondi E., Corallini F., Milani D., Grill V., Forti G., Capitani S., and Zauli G. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell. Mol. Life Sci. 61 (2004) 1965-1974
33. Kim J.H., Choi C., Benveniste E.N., and Kwon D. TRAIL induces MMP-9 expression via ERK activation in human astrocytoma cells. Biochem. Biophys. Res. Commun. 377 (2008) 195-199
34. Baader E., Toloczko A., Fuchs U., Schmid I., Beltinger C., Ehrhardt H., Debatin K.M., and Jeremias I. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res. 65 (2005) 7888-7895
35. Milani D., Zauli G., Rimondi E., Celeghini C., Marmiroli S., Narducci P., Capitani S., and Secchiero P. Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J. Neurochem. 86 (2003) 126-135
36. Belyanskaya L.L., Ziogas A., Hopkins-Donaldson S., Kurtz S., Simon H.U., Stahel R., and Zangemeister-Wittke U. TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Lung Cancer 60 (2008) 355-365
37. Hague A., Hicks D.J., Hasan F., Smartt H., Cohen G.M., Paraskeva C., and MacFarlane M. Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis. Br. J. Cancer 92 (2005) 736-742
38. Clohessy J.G., Zhuang J., de Boer J., Gil-Gomez G., and Brady H.J. Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J. Biol. Chem. 281 (2006) 5750-5759
39. Rosato R.R., Almenara J.A., Coe S., and Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 67 (2007) 9490-9500
40. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., and Trail P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64 (2004) 7099-7109
41. Rahmani M., Davis E.M., Bauer C., Dent P., and Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem. 280 (2005) 35217-35227
42. Vaculova A., Hofmanova J., Soucek K., and Kozubik A. Different modulation of TRAIL-induced apoptosis by inhibition of pro-survival pathways in TRAIL-sensitive and TRAIL-resistant colon cancer cells. FEBS Lett. 580 (2006) 6565-6569
43. Henson E.S., Gibson E.M., Villanueva J., Bristow N.A., Haney N., and Gibson S.B. Increased expression of Mcl-1 is responsible for the blockage of TRAIL-induced apoptosis mediated by EGF/ErbB1 signaling pathway. J. Cell. Biochem. 89 (2003) 1177-1192